NOTCH1 pathway activation contributes to the pathogenesis of over 60% of T-cell acute lymphoblastic leukemia (T-ALL). While Notch is thought to exert the majority of its effects through ...
T-cell therapy represents a groundbreaking advancement in the field of immuno-oncology. This innovative treatment involves ...
Orca Bio announces it met the primary endpoint in its pivotal Phase 3 clinical study for its lead allogeneic T-cell immunotherapy, Orca-T.
Galinpepimut-S therapy showed specific T-Cell immune responses for patients with acute myeloid leukemia in remission ...
The FDA made strides in R/R T-cell lymphoma and breast cancer. An AI tool aids pathologists and other positive updates in gastric cancer and NSCLC.
Oct. 7, 2024 — Fratricide-resistant CD7 CAR-T therapy by NUS proves effective ... risk in children with standard risk B-cell acute lymphoblastic leukemia (SR B-ALL), the most common childhood ...
University of Illinois Chicago scientists have redesigned a treatment for the most common pediatric leukemia to eliminate its ...
Fae went to school the day before her family learned she had cancer. Everything seemed so normal, and then…it wasn’t. Her ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback